These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 6190284)
21. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. Walter MA; Christ-Crain M; Eckard B; Schindler C; Nitzsche EU; Müller-Brand J; Müller B Eur J Clin Invest; 2004 May; 34(5):365-70. PubMed ID: 15147334 [TBL] [Abstract][Full Text] [Related]
22. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism. He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329 [TBL] [Abstract][Full Text] [Related]
24. [Dynamics of PBI behavior in blood serum of patients with Graves-Basedow disease and toxic nodular goiter during treatment with methimetazole]. Jaruga-Dolińska E; Zembrzuska Z; Korman E Endokrynol Pol; 1971; 22(6):535-43. PubMed ID: 4110630 [No Abstract] [Full Text] [Related]
25. Elevation of serum creatine kinase during treatment with antithyroid drugs in patients with hyperthyroidism due to Graves disease. A novel side effect of antithyroid drugs. Suzuki S; Ichikawa K; Nagai M; Mikoshiba M; Mori J; Kaneko A; Sekine R; Asanuma N; Hara M; Nishii Y; Yamauchi K; Aizawa T; Hashizume K Arch Intern Med; 1997 Mar; 157(6):693-6. PubMed ID: 9080924 [TBL] [Abstract][Full Text] [Related]
26. [Radioiodine therapy of recurrent hyperthyroidism in patients previously treated for diffuse toxic goiter with subtotal surgery]. Vestergaard H; Laurberg P Ugeskr Laeger; 1993 Aug; 155(31):2403-5. PubMed ID: 8346592 [TBL] [Abstract][Full Text] [Related]
27. [The inhibition test of thyroid function with triiodothyronine in hyperthyroid patients under medical therapy: comparison of the values obtained from measures of "early" uptake and in the organic phase]. Valentini F; Reschini E; Lodeserto A; Vivarelli S; Miedico D Folia Endocrinol; 1968 Aug; 21(4):396-403. PubMed ID: 4185869 [No Abstract] [Full Text] [Related]
28. [L.A.T.S. activity during hyperthyroidism. Apropos of 143 cases of Basedow's disease]. Letonturier P; Tourneur R; Sénécal P Ann Med Interne (Paris); 1974 May; 125(5):463-7. PubMed ID: 4140703 [No Abstract] [Full Text] [Related]
29. Treatment of Graves' hyperthyroidism--prognostic factors for outcome. Alfadda A; Malabu UH; El-Desouki MI; Al-Rubeaan KA; Al-Ruhaily AD; Fouda MA; Al-Maatouq MA; Sulimani RA Saudi Med J; 2007 Feb; 28(2):225-30. PubMed ID: 17268701 [TBL] [Abstract][Full Text] [Related]
30. Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Eckstein AK; Lax H; Lösch C; Glowacka D; Plicht M; Mann K; Esser J; Morgenthaler NG Clin Endocrinol (Oxf); 2007 Oct; 67(4):607-12. PubMed ID: 17880407 [TBL] [Abstract][Full Text] [Related]
31. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents]. Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933 [TBL] [Abstract][Full Text] [Related]
32. [Osteocalcin in diffuse toxic goiter]. Balabolkin MI; Khaiutina TL; Mkrtumian AM Ross Med Zh; 1992; (1):13-5. PubMed ID: 1377070 [TBL] [Abstract][Full Text] [Related]
33. [Proceedings: Effect of inorganic iodine on serum thyroxine concentration in Basedow's disease--in patients during treatment with antithyroid agents]. Ikeda H; Imai Y; Uchimura H; Matsuzaki F; Nagataki S Nihon Naibunpi Gakkai Zasshi; 1974 Feb; 50(2):408. PubMed ID: 4141670 [No Abstract] [Full Text] [Related]
34. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism. Franklyn JA; Daykin J; Holder R; Sheppard MC QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667 [TBL] [Abstract][Full Text] [Related]
35. [Combination of low doses of 131-iodine and synthetic antithyroid agents for prolonged treatment in Basedow's disease. Apropos of 165 cases]. Mitouze J; Jaffiol C; Baldet L; Ghachem M Rev Fr Endocrinol Clin; 1972; 13(4):339-61. PubMed ID: 4122472 [No Abstract] [Full Text] [Related]
36. An update on the pharmacological management of hyperthyroidism due to Graves' disease. Bartalena L; Tanda ML; Bogazzi F; Piantanida E; Lai A; Martino E Expert Opin Pharmacother; 2005 Jun; 6(6):851-61. PubMed ID: 15952916 [TBL] [Abstract][Full Text] [Related]
37. Prediction of response to medical therapy by serum soluble (pro)renin receptor levels in Graves' disease. Mizuguchi Y; Morimoto S; Kimura S; Takano N; Yamashita K; Seki Y; Bokuda K; Yatabe M; Yatabe J; Watanabe D; Ando T; Ichihara A PLoS One; 2018; 13(4):e0195464. PubMed ID: 29621332 [TBL] [Abstract][Full Text] [Related]
39. Ultrastructure of human thyroid. A study of normal thyroid, untreated and treated diffuse toxic goiter. Heimann P Acta Endocrinol (Copenh); 1966; 53():Suppl 110:1+. PubMed ID: 4162591 [No Abstract] [Full Text] [Related]
40. [Hypothyroidism following treatment of hyperthyroidism with radioactive iodine (I 131 )]. Gasiorowski W; Rusiecka-Wojciechowska E; Jeske E Minerva Med; 1973 Feb; 64(9):425-8. PubMed ID: 4121076 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]